Quick Answer
VERACYTE, INC. reported Total Revenue of $517.14 million for fiscal year 2025.
VERACYTE, INC. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $517.14M +16.0% |
$445.76M +23.5% |
$361.05M +21.8% |
$296.54M +35.1% |
$219.51M +86.8% |
$117.48M -2.4% |
| Revenue (ASC 606) | $517.14M +16.0% |
$445.76M +23.5% |
$361.05M +21.8% |
$296.54M +35.1% |
$219.51M +86.8% |
$117.48M -2.4% |
| Net Income | $66.35M +174.9% |
$24.14M +132.4% |
-$74.40M -103.5% |
-$36.56M +51.6% |
-$75.56M -116.5% |
-$34.91M -177.1% |
| Diluted EPS | $0.82 +164.5% |
$0.31 +130.4% |
-$1.02 -100.0% |
-$0.51 +54.1% |
-$1.11 -68.2% |
-$0.66 -144.4% |
| Total Assets | $1.41B +8.2% |
$1.30B +16.6% |
$1.11B -3.6% |
$1.16B -2.6% |
$1.19B +159.8% |
$457.16M +66.1% |
| Cash and Equivalents | $362.58M +51.7% |
$239.09M +10.5% |
$216.45M +40.3% |
$154.25M -10.9% |
$173.20M -50.4% |
$349.36M +119.3% |
| Long-Term Debt | — | — | — | — | $0.00 -100.0% |
$810.0K +16.7% |
| Stockholders Equity | $1.31B +11.4% |
$1.18B +12.6% |
$1.04B -2.9% |
$1.08B -1.9% |
$1.10B +160.3% |
$421.23M +75.9% |
| R&D Expense | $70.81M +2.2% |
$69.29M +20.9% |
$57.30M +41.1% |
$40.60M +36.1% |
$29.84M +73.5% |
$17.20M +15.8% |
| Operating Income | $57.78M +257.9% |
$16.14M +118.8% |
-$85.80M -108.8% |
-$41.08M +49.8% |
-$81.90M -131.4% |
-$35.39M -133.9% |
| Gross Profit | $362.53M +21.6% |
$298.14M +29.8% |
$229.68M +30.7% |
$175.68M | — | — |
| Shares Outstanding | 79.36M +2.0% |
77.77M +6.2% |
73.26M +1.8% |
71.96M +1.2% |
71.12M +22.2% |
58.20M +17.3% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $131.87M | +13.8% | +1.3% |
| Revenue (ASC 606) | September 30, 2025 | $131.87M | +13.8% | +1.3% |
| Net Income | September 30, 2025 | $19.14M | +26.3% | +2052.8% |
| Diluted EPS | September 30, 2025 | $0.24 | +26.3% | +2500.0% |
| Total Assets | September 30, 2025 | $1.37B | +7.3% | +1.8% |
| Cash and Equivalents | September 30, 2025 | $315.57M | +15.1% | +43.8% |
| Long-Term Debt | September 30, 2021 | $1.07M | +42.2% | +17.2% |
| Stockholders Equity | September 30, 2025 | $1.26B | +6.9% | +3.0% |
| R&D Expense | September 30, 2025 | $15.98M | -9.1% | -1.7% |
| Operating Income | September 30, 2025 | $22.95M | +90.9% | +535.6% |
| Gross Profit | September 30, 2025 | $91.28M | +15.5% | +1.7% |
| Shares Outstanding | September 30, 2025 | 79.03M | +2.0% | +0.6% |
- VERACYTE, INC. reported Total Revenue of $517.14 million for fiscal year 2025.
- VERACYTE, INC. showed an increase of +16.0% in Total Revenue compared to the prior fiscal year.
- VERACYTE, INC. reported Revenue (ASC 606) of $517.14 million for fiscal year 2025.
- VERACYTE, INC. showed an increase of +16.0% in Revenue (ASC 606) compared to the prior fiscal year.
- VERACYTE, INC. reported Net Income of $66.35 million for fiscal year 2025.
- VERACYTE, INC. showed an increase of +174.9% in Net Income compared to the prior fiscal year.
- VERACYTE, INC. reported Diluted EPS of $0.82 per share for fiscal year 2025.
- VERACYTE, INC. showed an increase of +164.5% in Diluted EPS compared to the prior fiscal year.
- VERACYTE, INC. reported Total Assets of $1.41 billion for fiscal year 2025.
- VERACYTE, INC. showed an increase of +8.2% in Total Assets compared to the prior fiscal year.
- VERACYTE, INC. reported Cash and Equivalents of $362.58 million for fiscal year 2025.
- VERACYTE, INC. showed an increase of +51.7% in Cash and Equivalents compared to the prior fiscal year.
- VERACYTE, INC. reported Long-Term Debt of $0.00 for fiscal year 2021.
- VERACYTE, INC. showed a decrease of -100.0% in Long-Term Debt compared to the prior fiscal year.
- VERACYTE, INC. reported Stockholders Equity of $1.31 billion for fiscal year 2025.
- VERACYTE, INC. showed an increase of +11.4% in Stockholders Equity compared to the prior fiscal year.
- VERACYTE, INC. reported R&D Expense of $70.81 million for fiscal year 2025.
- VERACYTE, INC. showed an increase of +2.2% in R&D Expense compared to the prior fiscal year.
- VERACYTE, INC. reported Operating Income of $57.78 million for fiscal year 2025.
- VERACYTE, INC. showed an increase of +257.9% in Operating Income compared to the prior fiscal year.
- VERACYTE, INC. reported Gross Profit of $362.53 million for fiscal year 2025.
- VERACYTE, INC. showed an increase of +21.6% in Gross Profit compared to the prior fiscal year.
- VERACYTE, INC. reported Shares Outstanding of 79.36 million shares for fiscal year 2025.
- VERACYTE, INC. showed an increase of +2.0% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: